- CompletedPhase IV
Treatment of inflammation inside the eye caused by an overactive immune system (autoimmune uveitis) using adalimumab
Autoimmune uveitis causes eye inflammation that can threaten your sight. High-dose steroids help, but they have serious long-term side effects. The ASTUTE trial is exploring whether an injection called adalimumab can calm eye swelling, protect your vision, and allow you to safely lower your daily steroid dose.
For: Autoimmune non-infectious uveitisUnited Kingdom · England - Active not recruitingPHASE3
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This study compares two treatments, abatacept and adalimumab, for adults with early, severe rheumatoid arthritis who haven't responded well to methotrexate. It aims to see which treatment is better at reducing arthritis symptoms and improving quality of life.
For: Rheumatoid ArthritisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
For: Rheumatoid ArthritisUnited States · Argentina · Australia - RecruitingPHASE2
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
This study looks at treating a specific type of arthritis, called immune checkpoint inhibitor-associated inflammatory arthritis (ir-IA), early with a medication called adalimumab. The aim is to see if early treatment can reduce swelling and pain, and lessen the need for steroid medicines.
For: Inflammatory Arthritis · Immune-related Adverse EventCanada - RecruitingPHASE3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
This study looks at a new medicine called risankizumab for children aged 5-17 with a type of arthritis called juvenile psoriatic arthritis (jPsA). It aims to see how safe and effective it is compared to an existing medicine, adalimumab. Participants will receive injections.
For: Juvenile Psoriatic ArthritisUnited States · Australia · Canada - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
For: Ulcerative ColitisUnited States · Australia · Austria - RecruitingPHASE4
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
This study looks at new ways to treat Crohn's disease. Researchers are testing if combining two medicines, vedolizumab and either adalimumab or ustekinumab, works better than vedolizumab alone for adults with moderate to severe Crohn's.
For: Crohn's DiseaseUnited States · Canada - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
This study is looking at a new medicine called baricitinib for children and young people aged 2 to 17 who have a specific eye condition called uveitis. We want to see if it's safe and helps reduce eye inflammation, especially for those who haven't responded well to other treatments.
For: UveitisFrance · Germany · Italy - Active not recruitingPHASE3
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
This study is testing a new medicine called ixekizumab for children aged 2-17 with two types of juvenile arthritis: enthesitis-related arthritis (including a form of arthritis affecting the spine) and juvenile psoriatic arthritis. We want to see if it's safe and helps improve their condition, comparing it to another common medicine, adalimumab.
For: Juvenile Psoriatic Arthritis · Enthesitis Related ArthritisArgentina · Belgium · Czechia - Active not recruitingPHASE3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.
For: Rheumatoid ArthritisUnited States · Argentina · Belgium